CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
6.37
-0.09 (-1.39%)
At close: Mar 18, 2026, 4:00 PM EDT
6.38
+0.01 (0.15%)
After-hours: Mar 18, 2026, 7:48 PM EDT
CorMedix Revenue
In the year 2025, CorMedix had annual revenue of $311.71M with 617.03% growth. CorMedix had revenue of $128.62M in the quarter ending December 31, 2025, with 312.10% growth.
Revenue (ttm)
$311.71M
Revenue Growth
+617.03%
P/S Ratio
1.62
Revenue / Employee
$1,631,984
Employees
191
Market Cap
503.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 311.71M | 268.24M | 617.03% |
| Dec 31, 2024 | 43.47M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
| Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
| Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
| Dec 31, 2019 | 283.27K | -146.53K | -34.09% |
| Dec 31, 2018 | 429.80K | 100.47K | 30.51% |
| Dec 31, 2017 | 329.33K | 105.22K | 46.95% |
| Dec 31, 2016 | 224.11K | 13.98K | 6.65% |
| Dec 31, 2015 | 210.13K | 20.86K | 11.02% |
| Dec 31, 2014 | 189.27K | 187.27K | 9,358.97% |
| Dec 31, 2013 | 2.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 294.28M |
| Vanda Pharmaceuticals | 216.11M |
| ADC Therapeutics | 81.36M |
| Verastem | 30.91M |
| DBV Technologies | 5.50M |
| Upstream Bio | 2.80M |
| Lyell Immunopharma | 36.00K |
| Allogene Therapeutics | 22.00K |
CRMD News
- 13 days ago - CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - CorMedix stock drops after earnings: is this dip a buy before key catalyst? - Invezz
- 13 days ago - CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 16 days ago - CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - GlobeNewsWire
- 4 weeks ago - CorMedix Inc. (CRMD) Analyst/Investor Day Transcript - Seeking Alpha
- 4 weeks ago - CorMedix to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - CorMedix Therapeutics Announces Share Repurchase Program - GlobeNewsWire
- 6 weeks ago - CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 - GlobeNewsWire